Company identifies unique two-part extraction and transdermal delivery process
VANCOUVER, BC (GLOBE NEWSWIRE – January 18, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to announce a second provisional patent for a proprietary two-part processing method that involves the extraction and transdermal delivery of psilocybin active components.
The extraction process uses a highly viscous material to isolate key components of psychedelic mushrooms and dissolves the psilocybin into a molecular solution. Using the same energy, the active ingredients are then repelled into the skin when applied topically. Due to the skin’s highly permeable membrane, Optimi’s solution has a natural time-release effect, which allows for a more sustained release into the body and provides a patient with the ability to experience the desired outcome for longer periods of time.
As Chief Science Office Justin Kirkland explains, “The most novel part of this process is that we are performing two very different functions with a single unique component. This component works much like the attraction and repulsion properties of a magnet with a North and South end. We leverage this energy to perform two functions. First, the attraction energy will extract psilocybin out of the mushroom. Second, when this same material is applied to the skin, it will advance the drug through the skin and into the bloodstream.”
Containing all GRAS certified ingredients, this solution can then be loaded into our proprietary drug delivery system for direct passage through the skin into the bloodstream. Transdermal application avoids the first pass metabolism and degradation of psilocybin by the liver that occurs with traditional oral drug delivery, which increases bioavailability of the active ingredient.
In the continued effort to champion all things natural, Optimi’s delivery system has been designed to require no additional shuttling agents. Instead, the repulsion technology steadily pushes the active ingredient through the various layers of the skin, and treatment begins almost immediately upon application. This new process will help to reduce costs and resources while providing patients with a superior product.
Optimi is focused on providing patients with a safe, consistent, and pure psychedelic product. Developing multiple extraction and delivery system methods is part of the Company’s commitment to ensuring patients have options when deciding their treatment.
“This unique chemistry provides improved bioavailability of Optimi’s psilocybin,” said Optimi CEO Bill Ciprick. “Our IP is evidence of Optimi Health’s continued commitment to sustainability by using green chemistry to achieve both the extraction and topical formulations.” Mr. Ciprick adds, “As patient access remains the focal point among regulators, lobbyists and Companies such as our own, we look forward to being able to provide our variety of therapies to those in need.”
On Behalf of the Board of Directors,
Chief Executive Officer
Optimi Health Corp.
ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness markets. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two facilities comprising a total of 20,000 square feet nearing completion in Princeton, British Columbia. To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of Psilocybin and Psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also applied for a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of Psilocybin and Psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production. Find out more at: https://optimihealth.ca/.
FOR FURTHER INFORMATION CONTACT:
This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to the Company’s potential Nasdaq listing, the dealer’s license application, activities proposed to be conducted under the Company’s research exemption and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.
Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Final Prospectus dated February 12, 2021. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement. Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
The CSE does not accept responsibility for the adequacy or accuracy of this release.